P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies

Moreno, David F.; Oriol, Albert; Rubia, Javier de la; Hernández, Miguel T.; Iñigo, Belén; Palomera, Luis; Arriba, Felipe de; González, Yolanda; Teruel, Ana Isabel; Granell, Miquel; Guía, Ana López de la; Mayol, Antonia Sampol; Sureda, Anna; Gutiérrez, Norma C.; Calasanz, María José; Ramos, María Luisa Martín; Mateos, María‐Victoria; San-Miguel, Jesús F.; Lahuerta, Juan José; Bladé, J; Rosiñol, Laura

doi:10.1016/s2152-2650(21)02305-3

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, an improvement was observed in the SR group. These findings are in line with the results of other authors who found that t(11;14) patients did not benefit as much from new treatments as did other myeloma subtypes [20,24,25,33,34].…”

Section: Discussionsupporting

confidence: 92%

“…In addition, a subanalysis conducted within the Spanish GEM2005MENOS65 and GEM2012 trials of transplant-eligible patients revealed similar responses and outcomes for patients with t (11;14) and SR when they received conventional chemotherapy. However, the efficacy was lower for patients with t (11;14) when treated with novel schemes, such as VTD or VRD [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the pre-novel-agent era, many authors agreed that patients with MM and t(11;14) had a favorable outcome [5,6,8,10,18]. However, in the novel-agent era, although treatments such as proteasome inhibitors (PIs) and immunomodulators (IMIDs) have improved the survival of most patients with MM, it is not clear whether this benefit also accrues to patients with t (11;14) [15,[19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multiple myeloma with t(11;14): impact of novel agents on outcome

et al. 2023

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: (1) t(11;14); (2) high-risk chromosomal abnormalities; and (3) standard risk (SR). After 80.1 months (1.2–273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75.8 vs. 87.2 months; P = 0.438). Treatment of MM t(11;14) with novel agents did not improve their overall response rate (ORR) or complete response (CR) compared with those who received conventional therapy (ORR: 87.2 vs. 79.5%, P = 0.336; CR: 23.4 vs. 12.8%, P = 0.215). This effect translated into a similar PFS (39.6 vs. 30.0 months; P = 0.450) and OS (107.6 vs. 75.7 months; P = 0.175). In summary, MM t(11;14) patients did not benefit from the introduction of novel agents as much as SR patients did, indicating that other therapies are needed to improve their outcomes.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple myeloma with t(11;14): impact of novel agents on outcome

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the pre-novel-agent era, many authors agreed that patients with MM and t (11;14) had a favorable outcome (5,6,8,10,18). However, in the novel-agent era, although treatments such as proteasome inhibitors (PIs) and immunomodulators (IMIDs) have improved the survival of most patients with MM, it is not clear whether this bene t also accrues to patients with t (11;14) (15,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34).…”

Section: Introductionmentioning

confidence: 99%

Multiple myeloma and t(11;14): prognostic significance and impact of novel agents on response and survival.

Puertas

González‐Calle

Sobejano

et al. 2022

Preprint

View full text Add to dashboard Cite

Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.6% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: 1) t(11;14); 2) high-risk chromosomal abnormalities; and 3) standard risk (SR). After 80.1 months (1.2-273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75.8 vs. 87.2 months; P = 0.438). However, in ISS-1 stage patients, MM t(11;14) individuals had shorter OS than those in the SR group (62.9 vs. 126.7 months; P = 0.004). Treatment of MM t(11;14) with novel agents did not improve their overall response rate (ORR) or complete response (CR) compared with those who received conventional therapy (ORR: 87.2% vs. 79.5%, P = 0.336; CR: 23.4% vs. 12.8%, P = 0.215). This effect translated into similar PFS (39.6 vs. 30.0 months; P = 0.450) and OS (107.6 vs. 75.7 months; P = 0.175). In summary, MM t(11;14) patients did not benefit from the introduction of novel agents as much as SR patients did, indicating that other therapies are needed if their outcome is to be improved.

show abstract

P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies

Cited by 2 publications

References 0 publications

Multiple myeloma with t(11;14): impact of novel agents on outcome

Multiple myeloma with t(11;14): impact of novel agents on outcome

Multiple myeloma and t(11;14): prognostic significance and impact of novel agents on response and survival.

Contact Info

Product

Resources

About